Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06799286 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer

StatusCompleted
PhasePhase 1
Started2025-05-07
View on ClinicalTrials.gov ↗

Amendment history

2026-09-25
Trial completed
Primary completion confirmed: September 2026 (last estimated May 2027)
2026-05-11
Study Status, Outcome Measures, IPDSharing v4
Secondary endpointsdetails revised at 7 of 7 entries
2025-08-25
Recruiting→Active, Not Recruiting Study Status, Contacts/Locations v3
Trial statusRecruiting→Active, Not Recruiting
Study sites5 entries, revised
ShandongLocal CancerInstitution Hospital- 0003 LinYiLocal CancerInstitution Hospital- 0001 SirLocal RunInstitution Run- Shaw0005 Local HospitalInstitution of- Zhejiang University School of Medicine Shanghai East Hospital0002
2025-06-05
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-07-31→confirmed 2025-05-07
Study sites5 entries, revised
LocalShandong InstitutionCancer -Hospital LinYi 0003Cancer Hospital LocalSir InstitutionRun -Run 0001Shaw Hospital of Zhejiang University School of Medicine LocalShanghai InstitutionEast - 0005 Local Institution - 0002Hospital
2025-03-20
Study Status, Contacts/Locations, References v1
Study sites1→5
2025-01-24
Original filing
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy of BMS-986489 in Chinese participants with R/R SCLC (Relapsed/Refractory Small Cell Lung Cancer).
Trial Details
NCT Number NCT06799286
Lead Sponsor Bristol-Myers Squibb
Conditions Small Cell Lung Carcinoma
Enrollment 10 participants
Start Date 2025-05-07
Primary Completion 2026-09-09 (estimated)
Study Completion 2026-09-09 (estimated)
Updated on ClinicalTrials.gov 2026-09-24